Stockscreener 앱 받기
113.31
2.07%
-2.40
Incyte Corp 주식(INCY)의 최신 뉴스
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy - Zacks Investment Research
An experimental drug combination showed a 71% response rate in colorectal cancer. - Stock Titan
Incyte Corp. Company & People | INCY - Barron's
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - Via TT
Incyte (NasdaqGS:INCY) Stock Price - Simply Wall Street
Incyte Corp. Research & Ratings | INCY - Barron's
Incyte Corp. Advanced Charts | INCY - Barron's
Incyte Corp. Financials | INCY - Barron's
Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan
Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance
Incyte Corp. Stock Grades | INCY - Barron's
Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - TradingView
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
Mission Bio Showcases Tapestri Across Drug Discovery and Clinical Development at World CDx Summit - Business Wire
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan
Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan
Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan
Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan
Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
1.42%
2.04%
자본화:
|
볼륨(24시간):